FDA Grants Approval to ALX Oncology’s Novel EGFR-Targeting Antibody-Drug Conjugate
ALX Oncology has announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ALX2004. This clearance paves the way for the company to begin Phase 1 clinical trials of its first antibody-drug conjugate (ADC), ALX2004.
ALX2004 is designed to treat solid tumors that express the epidermal growth factor receptor. It is the first drug developed entirely using ALX Oncology’s in-house proprietary linker-payload platform and represents a major milestone in the company’s therapeutic pipeline.
The Phase 1 will include a dose-escalation and expansion phase, evaluating ALX2004 as a single-agent therapy. The drug has been engineered to deliver a potent chemotherapy payload directly to tumor cells while aiming to reduce harmful effects on healthy tissues.
EGFR is a protein helps regulate cell growth. It is often overexpressed in various cancers, including breast, colorectal, head and neck, and non-small cell lung cancer. While EGFR has been targeted by several approved therapies, there are currently no approved ADCs directed at this receptor. Previous efforts in this area have faced challenges such as non-specific toxicity and limitations in drug design.
ALX2004 incorporates a stabilised linker and a proprietary topoisomerase I inhibitor payload developed to maximise tumor cell killing while minimising damage to normal tissues. This next-generation ADC aims to address limitations seen in earlier EGFR-targeted approaches and has shown strong anti-tumor activity in preclinical studies.
